Dimitri Novitzky1, Zhibao Mi, Qing Sun, Joseph F Collins, David K C Cooper. 1. 1 Formerly Department of Cardiac Surgery, University of South Florida, Tampa, FL. 2 Cooperative Studies Program Coordinating Center, VA Medical Center, Perry Point, MD. 3 Department of Surgery, Children's Hospital of Pittsburgh, Pittsburgh, PA. 4 Thomas E. Starzl Transplantation Institute, University of Pittsburgh, Pittsburgh, PA. 5 Address correspondence to: David K.C. Cooper, M.D., Ph.D., F.R.C.S., Thomas E. Starzl Transplantation Institute, Starzl Biomedical Science Tower, W1543, University of Pittsburgh Medical Center, 200 Lothrop St, Pittsburgh, PA 15261.
Abstract
BACKGROUND: Hormonal therapy to the brain-dead potential organ donor can include thyroid hormone (triiodothyronine [T3] or levothyroxine [T4]), corticosteroids, antidiuretic hormone, and insulin. METHODS: Data on 66,629 donors (2000-2009) were retrospectively reviewed. Documentation on T3/T4 was available in 63,593 (study 1), but 23,469 had incomplete documentation of other hormones. In 40,124, details of all four hormones were recorded (study 2). In this cohort, group A (received T3/T4) consisted of 23,022, and group B (no T3/T4) consisted of 17,102 donors. A multivariate analysis was performed to determine whether age, sex, ethnicity, cause of death, body mass index, Organ Procurement Organization region, or other hormonal therapy influenced procurement. Posttransplantation organ graft survival at 1 and 12 months was compared. RESULTS: In study 1, 30,962 (48.69%) received T3/T4, providing a mean of 3.35 organs per donor, and 32,631 (51.31%) did not receive T3/T4, providing a mean of 2.97 organs per donor, an increase of 12.8% of organs from T3/T4-treated donors (P<0.0001). In study 2, group A provided a mean of 3.31 organs per donor and group B provided a mean of 2.87 organs per donor, an increase of 15.3% in group A (P<0.0001). T3/T4 therapy was associated with procurement of significantly greater numbers of hearts, lungs, kidneys, pancreases, and intestines, but not livers. Multivariate analysis indicated a beneficial effect of T3/T4 independent of other factors (P<0.0001). T3/T4 therapy of the donor was associated with improved posttransplantation graft survival or no difference in survival, except for pancreas recipient (but not graft) survival at 12 months in study 2. CONCLUSION: T3/T4 therapy results in more transplantable organs, with no detriment to posttransplantation graft survival.
BACKGROUND: Hormonal therapy to the brain-dead potential organ donor can include thyroid hormone (triiodothyronine [T3] or levothyroxine [T4]), corticosteroids, antidiuretic hormone, and insulin. METHODS: Data on 66,629 donors (2000-2009) were retrospectively reviewed. Documentation on T3/T4 was available in 63,593 (study 1), but 23,469 had incomplete documentation of other hormones. In 40,124, details of all four hormones were recorded (study 2). In this cohort, group A (received T3/T4) consisted of 23,022, and group B (no T3/T4) consisted of 17,102 donors. A multivariate analysis was performed to determine whether age, sex, ethnicity, cause of death, body mass index, Organ Procurement Organization region, or other hormonal therapy influenced procurement. Posttransplantation organ graft survival at 1 and 12 months was compared. RESULTS: In study 1, 30,962 (48.69%) received T3/T4, providing a mean of 3.35 organs per donor, and 32,631 (51.31%) did not receive T3/T4, providing a mean of 2.97 organs per donor, an increase of 12.8% of organs from T3/T4-treated donors (P<0.0001). In study 2, group A provided a mean of 3.31 organs per donor and group B provided a mean of 2.87 organs per donor, an increase of 15.3% in group A (P<0.0001). T3/T4 therapy was associated with procurement of significantly greater numbers of hearts, lungs, kidneys, pancreases, and intestines, but not livers. Multivariate analysis indicated a beneficial effect of T3/T4 independent of other factors (P<0.0001). T3/T4 therapy of the donor was associated with improved posttransplantation graft survival or no difference in survival, except for pancreas recipient (but not graft) survival at 12 months in study 2. CONCLUSION:T3/T4 therapy results in more transplantable organs, with no detriment to posttransplantation graft survival.
Authors: Mason T Breitzig; Matthew D Alleyn; Richard F Lockey; Narasaiah Kolliputi Journal: Am J Physiol Lung Cell Mol Physiol Date: 2018-09-27 Impact factor: 5.464
Authors: Hayato Iwase; Burcin Ekser; Vikas Satyananda; Mohamed Ezzelarab; David K C Cooper Journal: Xenotransplantation Date: 2014-07-08 Impact factor: 3.907
Authors: Lauren B Cooper; Carmelo A Milano; Melissa Williams; Wendy Swafford; Donna Croezen; Adrian B Van Bakel; Joseph G Rogers; Chetan B Patel Journal: Clin Transplant Date: 2016-12 Impact factor: 2.863
Authors: Nicholas Murphy; Charles Weijer; Jennifer Chandler; Frédérick D'Aragon; Andrew Healey; Matthew J Weiss; Marat Slessarev Journal: Can J Anaesth Date: 2022-07-13 Impact factor: 6.713
Authors: Amit Bery; Gary Marklin; Akinobu Itoh; Daniel Kreisel; Tsuyoshi Takahashi; Bryan F Meyers; Ruben Nava; Benjamin D Kozower; Hailey Shepherd; G Alexander Patterson; Varun Puri Journal: Ann Thorac Surg Date: 2021-01-07 Impact factor: 5.102